Regional and supply-chain research

Vaccine Diagnostic Veterinary Biologics Keyword Candidate Study

Vaccine Diagnostic Veterinary Biologics Keyword Candidate Study. A dated 30-record cohort study compares composition, parent sets and evidence coverage. Comparative structure study; archive date 2026-10-16.

Revision and archive snapshot: 2026-10-16

Swipe tables sideways to see all columns.

Research findings

Comparative structure study

The largest recorded reporting jurisdiction, Jiangsu, contains 9 records (30.0% of this 30-record cohort). The remaining cohort contains 21 records. The comparison concerns archive composition.

The recorded chain role label Biomedicine and medical devices / Complete systems and use-case applications accounts for 86.7% here (26/30), compared with 7.1% in the parent set (1,373/19,297), an absolute gap of 79.6 percentage points.

13/30 companies link to pages with existing source-supported excerpts (43.3% of the cohort). The other 17 records remain usable for archive composition, but do not support new operating case studies.

6 keyword candidates match only a company name, with no matching term in recorded products or sub-industry fields. Product evidence is needed before treating these as operating businesses in this segment.

Company cohortDirectly linked pagesShare of public archiveArchive date
30300.2%2026-10-16

An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.

Comparable sets and compositional differences

The parent set, All public archive records, contains 19,297 records. This cohort contributes 30 (0.2%); 19,267 records remain after excluding it.

CategoryCohort count/baseReference: All public archive recordsGap (pp)Representation ratioRest count/base
chain role · Biomedicine and medical devices / Complete systems and use-case applications26/30 · 86.7%1,373/19,297 · 7.1%+79.612.181,347/19,267
industry · Biomedicine25/30 · 83.3%1,721/19,297 · 8.9%+74.49.341,696/19,267
sub-industry · Biomedicine9/30 · 30.0%699/19,297 · 3.6%+26.48.28690/19,267
sub-industry · In vitro diagnostics5/30 · 16.7%32/19,297 · 0.2%+16.5100.5127/19,267
reporting jurisdiction · Jiangsu9/30 · 30.0%3,025/19,297 · 15.7%+14.31.913,016/19,267
reporting jurisdiction · Shenzhen5/30 · 16.7%1,398/19,297 · 7.2%+9.42.301,393/19,267

Ratio of label participation, not market share; multi-label counts overlap.

Excluding this cohort, the recorded chain role label Biomedicine and medical devices / Complete systems and use-case applications covers 1,347/19,267 remaining records (7.0%), an absolute gap of 79.7 percentage points from this cohort.

Concentration and cross-sectional structure

The full reporting jurisdiction distribution has 14 labels; the top 3 contain 17/30 records (56.7%).Other known labels contain 13 records.

For 30 records with known labels, the effective category count is 6.8, versus 14 actual labels. Definitions and scope are in the methodology.

The table shows ten labels; 4 others are included in the calculations above.

Recorded labelRecordsShare of cohort
Jiangsu930.0%
Shenzhen516.7%
Hunan310.0%
Beijing26.7%
Shandong26.7%
Shanghai13.3%
Sichuan13.3%
Tianjin13.3%
Guangdong13.3%
Xinjiang Production and Construction Corps13.3%

Record counts do not rank supply capability or economic size.

The largest intersection, Jiangsu × Biomedicine, contains 6 records, or 66.7% of the 9 records carrying the Jiangsu label.

reporting jurisdictionindustryIntersection recordsCohort share
JiangsuBiomedicine620.0%
ShenzhenBiomedicine413.3%
HunanBiomedicine310.0%
BeijingBiomedicine26.7%
ShandongBiomedicine26.7%
ShanghaiBiomedicine13.3%
SichuanBiomedicine13.3%
TianjinBiomedicine13.3%

A cell contains company IDs carrying both labels. It does not establish procurement, supply or investment relationships between firms. Multi-label cells may overlap.

This page displays 8 of the full cross-tab’s 18 non-empty cells; the other 10 remain in the analysis.

Evidence coverage and strength of conclusions

Record fieldNon-empty/cohortCompletion
Company name30/30100.0%
reporting jurisdiction30/30100.0%
industry30/30100.0%
Recorded products30/30100.0%
sub-industry30/30100.0%
Chain labels30/30100.0%

Non-empty fields are not necessarily accurate or supported by originals.

Scope of source supportCount
Profiles with source-supported excerpts13
Distinct corresponding companies13
Reviewed Chinese/English paragraph pairs13

Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.

Transparent rule reminderRecordsCohort share
Contains registration-narrative wording13.3%

A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.

Matched fieldCandidatesCohort share
Company name620.0%
Recorded products2066.7%
Sub-industry723.3%

An ID may match several fields, so counts may exceed the cohort total. Matches establish search relevance only.

Among the translated non-broad query terms, “biological products” has the most matches: 14/30. Name, product and sub-industry fields match 6, 4 and 5 records respectively; the largest field is name. Fields can overlap, and a term remains a search link rather than verified business activity.

Selected query termCandidates/shareName matchesProduct fieldSub-industry
biological products14 · 46.7%645

Selected broad terms and specific segment terms, not the full query. Terms and fields can overlap and must not be summed. Counts show lexical sensitivity; no records are removed without primary evidence.

6 candidates match only a name, or lose all product-field matches after the full company name is removed while sub-industry also has no hit. This transparent string test locates copied company descriptions; it does not establish that a company does not operate the business.

Intersection with 2026 local lists

10 of this cohort’s 30 records link through existing company-ID mappings to 2026 lists from all jurisdictions (33.3%). This intersection measures list linkage, not successful recognition or company growth.

Observation setList recordsNew-applicant recordsReview recordsMapped company IDs
National list records linked to this cohort’s IDs1001010

List rows and company IDs are separate counts, not new firms or final recognition.

Stored 2026 local-recommendation records, sources and stage definitions

Recorded roles and delivery checks

Delivery framework, stages and original sources

Related studies and shared records

Shared records with Poct Biosensor Diagnostics Keyword Candidate Study: 11; records in this cohort but outside that set: 19. The intersection/union ratio is 34.4%, a measure of label overlap rather than business collaboration. Read comparison

Shared records with Industrial Solvents Reagents High Purity Chemicals Keyword Candidate Study: 12; records in this cohort but outside that set: 18. The intersection/union ratio is 18.8%, a measure of label overlap rather than business collaboration. Read comparison

Company samples and record links

CompanyJurisdictionRecorded industry
Xinghua GL Stevia Co., Ltd.JiangsuBiomedicine
Hunan Runkun Pharmaceutical Co., Ltd.HunanBiomedicine
Xinjiang Chen Guang Biotech Co., Ltd.Xinjiang Production and Construction CorpsBiomedicine
Jiangsu Xinruibei Biotechnology Co., Ltd.JiangsuAdvanced chemicals
Guangzhou LBP Medicine Science & Technology Co., Ltd.GuangdongBiomedicine
Shenzhen Bioeasy Biotechnology Co., Ltd.ShenzhenBiomedicine
Lisure Science(Suzhou) Co., Ltd.JiangsuBiomedicine
Rayto Life and Analytical Sciences Co., Ltd.ShenzhenBiomedicine

Stable-ID samples, not rankings; metrics use the full cohort.

Directly related profiles and reports

Methodology

Read ID deduplication, comparison, batch and evidence definitions